339 results on '"Schönermarck, Ulf"'
Search Results
2. Sapovirus: an emerging pathogen in kidney transplant recipients?
3. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange
4. Severe hypertension and (renal) thrombotic microangiopathy: solving the puzzle
5. Features of Postpartum Hemorrhage-Associated Thrombotic Microangiopathy and Role of Short-Term Complement Inhibition
6. Thrombotische Mikroangiopathien in der operativen Intensivmedizin unter besonderer Berücksichtigung des atypischen hämolytisch-urämischen Syndroms
7. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
8. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
9. Klinisches Bild und diagnostisches Vorgehen bei entzündlichen Gefäßerkrankungen
10. Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis
11. HLA-DRB1∗16 and -DQB1∗05 alleles are strongly associated with autoimmune pancreatitis in a cohort of hundred patients
12. Alternate‐day dosing of caplacizumab for immune‐mediated thrombotic thrombocytopenic purpura
13. Polyomavirus exerts detrimental effects on renal function in patients after lung transplantation
14. The Joint Vasculitis Registry in German-speaking countries (GeVas): subgroup analysis of 195 GCA patients
15. Strategien zur effektiven und nebenwirkungsarmen Therapie ANCA-assoziierter Vaskulitiden
16. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
17. Chronische Nierenerkrankung
18. Autoren
19. Rituximab in Membranous Nephropathy
20. Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC–MS/MS method in human serum
21. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange
22. Large potassium shifts during dialysis enhance cardiac repolarization instability
23. ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP
24. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
25. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
26. Sapovirus – An emerging pathogen in renal transplant recipients?
27. Correct use of non-indexed eGFR for drug dosing and renal drug-related problems at hospital admission
28. Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis
29. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis
30. Kidney transplantation in ANCA-associated vasculitis
31. Avacopan in Anti-Neutrophil Cytoplasmic Autoantibodies–Associated Vasculitis in a Real-World Setting
32. The Joint Vasculitis Registry in German-speaking countries (GeVas): subgroup analysis of 266 AAV-patients
33. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
34. Autoren
35. Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study
36. Autoren
37. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
38. Thrombotische Mikroangiopathien in der operativen Intensivmedizin unter besonderer Berücksichtigung des atypischen hämolytisch-urämischen Syndroms
39. Corrigendum: Disqualification of donor and recipient candidates from the living kidney donation program: Experience of a single-center in Germany
40. SARS-CoV-2 vaccination in haemodialysis patients: Insides from a prospective study comparing mRNA and viral vector vaccines
41. Erratum to “Features of Postpartum Hemorrhage-Associated Thrombotic Microangiopathy and Role of Short-Term Complement Inhibition” [Kidney International Reports Volume 9, Issue 4, April 2024, Pages 919-928]
42. Drug-induced CYP-Induction as Therapy for Tacrolimus Intoxication
43. Disqualification of Donor and Recipient Candidates From the Living Kidney Donation Program: Experience of a Single-Center in Germany
44. Challenges and Considerations in Managing Thrombotic Microangiopathy and Disseminated Intravascular Coagulation in Postpartum Hemorrhage
45. Herz oder Nieren? Finden Sie heraus, woran es liegt!
46. SARS-CoV-2 Vaccine Response in Patients With Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
47. Humoral response after SARS-CoV-2 booster vaccination in haemodialysis patients with and without prior infection
48. Diminished Short- and Long-Term Antibody Response after SARS-CoV-2 Vaccination in Hemodialysis Patients
49. HLA-DRB1*16 and -DQB1*05 alleles are strongly associated with autoimmune pancreatitis in a cohort of hundred patients
50. Eiweiß im Harn
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.